Tesamorelin vs Cagrilintide

Tesamorelin and Cagrilintide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Tesamorelin (tesamorelin acetate) is a synthetic analog of human growth hormone-releasing hormone (GHRH), comprising 44 amino acids. It is the only FDA-approved treatment for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, marketed under the brand name Egrifta. By stimulating the endogenous production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), Tesamorelin effectively reduces visceral adipose tissue, which is critical for improving metabolic outcomes in affected individuals. The efficacy of Tesamorelin was demonstrated in Phase 3 trials, where participants experienced significant reductions in visceral fat over a 26-week period, with a generally favorable safety profile. Notably, the recent FDA approval of Egrifta WR, a weekly-reconstitution formulation, in March 2025, reflects ongoing advancements in its therapeutic application. Key findings suggest that Tesamorelin not only reduces visceral adipose tissue but may also enhance skeletal muscle area and density, particularly in patients on integrase strand transfer inhibitor (INSTI)-based HIV regimens.

Cagrilintide is a long-acting synthetic analog of human amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Developed by Novo Nordisk, Cagrilintide is being explored both as a standalone treatment and in combination with semaglutide (CagriSema). This combination leverages complementary mechanisms to regulate appetite and promote weight loss, with amylin influencing hindbrain satiety circuits and GLP-1 targeting hypothalamic and gastrointestinal pathways. The REDEFINE Phase 3 program highlighted the efficacy of CagriSema, demonstrating an impressive average weight loss of 20.4% over 68 weeks. As of 2026, Novo Nordisk is seeking FDA approval for this combination therapy, which preliminary data suggest may offer superior outcomes compared to semaglutide alone. The ongoing research into Cagrilintide underscores its potential as a standalone weight loss agent, further emphasizing its role in addressing obesity and metabolic health.

While Tesamorelin and Cagrilintide are both peptides investigated in metabolic research, they target distinct areas of study. Tesamorelin's primary focus is on body composition, particularly in the context of HIV-related lipodystrophy, where it has shown efficacy in reducing visceral fat and improving metabolic profiles. Conversely, Cagrilintide is primarily aimed at weight management and metabolic health, with research indicating its effectiveness in appetite regulation and weight loss strategies. This divergence in research applications highlights the specialized roles each peptide plays within the broader field of metabolic research, allowing for targeted investigations based on specific therapeutic needs.

Safety profiles for Tesamorelin and Cagrilintide reflect their distinct mechanisms and applications. For Tesamorelin, common adverse events include headache, nausea, and flu-like symptoms. Additionally, it may increase blood glucose levels, necessitating careful monitoring in diabetic populations. The FDA categorizes Tesamorelin as pregnancy category X, indicating potential risks to fetal development. In contrast, Cagrilintide is associated with gastrointestinal adverse events, with a reported incidence of 79.6% in the CagriSema group compared to 39.9% in placebo, primarily involving mild-to-moderate symptoms such as nausea, vomiting, diarrhea, and constipation. Furthermore, Cagrilintide shares a similar safety profile with the GLP-1 class, including potential risks for pancreatitis, gallbladder events, and thyroid C-cell tumors observed in rodent studies. These safety considerations are vital for researchers to evaluate when considering the use of these peptides in clinical or preclinical studies.